Roche licenses rights to Simcere Zaiming’s SIM-0660
Immune Simcere Zaiming Pharmaceutical Co. Ltd., a subsidiary of Simcere Pharmaceutical Group Ltd., has entered into an exclusive…
Roche nabs Simcere’s preclinical trispecific TCE in $1.53B deal
To read the full article sign up for free or sign in. Sep. 2, 2026 By Marian (YoonJee)…
Roche and GE Healthcare launch NAVIFY Tumor Board with
Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc](https://www.europesays.com/ch/wp-content/uploads/2026/08/1787315473_696b7c85-2d23-4f5e-a77b-8c6b2fa45d47-380x220.png)
Roche’s US subsidiary Genentech announces manufacturing
New facility in Hillsboro, Oregon for the assembly of injectable medicines and delivery devices will further advance end-to-end…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc](https://www.europesays.com/ch/wp-content/uploads/2026/08/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47-380x220.png)
Roche introduces cobas infinity edge, a new open digital
Roche’s new cloud-based platform connects patient test results, medical records and third-party applications, allowing professionals to monitor patients’…
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2,…
CHMP recommends EU approval of Roche’s Susvimo, the first
Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye…
CHMP recommends EU approval of Roche’s Susvimo, the first
Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye…
CHMP recommends EU approval of Roche’s Susvimo, the first
Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye…
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2,…
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2,…
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2,…